Scientists test re-engineered immune cells as a new weapon against tough leukemia
NCT ID NCT06326021
Summary
This early-stage trial is testing the safety and finding the right dose of a new type of CAR-T cell therapy called FL-33 for people with acute myeloid leukemia that has come back or hasn't responded to other treatments. The study will enroll up to 27 adults and children to see how their bodies handle the treatment and to look for early signs that it might help control the cancer. A key part of the plan is for participants to have a stem cell transplant after receiving the CAR-T therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY/RELAPSED ACUTE MYELOID LEUKAEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BeijingGoBroadH
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Liquan Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 201418, China
-
The General Hospital of Western Theater Command PLA
NOT_YET_RECRUITINGChengdu, Sichuan, 610083, China
-
Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200435, China
Conditions
Explore the condition pages connected to this study.